PCSK9 and Hypercholesterolemia: MicroRNA-483 targeting 3’ untranslated region of PCSK9 mRNA inhibits hepatic PCSK9 expression, resulting in increased LDLR expression and LDL uptake, which ameliorates hypercholesterolemia and atherosclerosis.